Medication Management for Dementia

Introduction to Dementia Care

• Providing predictable routines, such as meals, exercise, and bedtime, is recommended for patients with mild to moderate dementia to support their daily activities, as suggested by the American College of Physicians and other authorities 1, 2
• Breaking complex tasks into simple steps and using distraction and redirection for problematic behaviors are suggested as strategies to support patients with dementia, with a strength of evidence supporting these non-pharmacological interventions 1, 2
• Environmental modifications, such as installing safety locks on doors and gates, using color-coded or graphic labels as orientation cues, and installing grab bars in bathrooms, can help prevent accidents and improve safety for patients with dementia, with a high level of evidence supporting these modifications 1, 2

Pharmacological Management

• Donepezil is recommended as the first-line medication for patients with Alzheimer's disease, with a dosing protocol starting at 5 mg once daily, and target dose of 10 mg once daily, as recommended by the American College of Physicians and other authorities 3, 4
• Alternative options for mild to moderate Alzheimer's disease include Rivastigmine 1.5-6 mg twice daily or Galantamine 4-12 mg twice daily, with a moderate level of evidence supporting these alternatives 3, 4
• For moderate to severe Alzheimer's disease, donepezil 5-10 mg daily is recommended, with the option to increase to 23 mg daily after at least 3 months on 10 mg, and consideration of adding memantine for combination therapy, with a high level of evidence supporting this approach 3, 4
• The following table summarizes the dosing regimens for cholinesterase inhibitors:

• Cholinesterase inhibitors commonly cause cholinergic side effects, including gastrointestinal symptoms, dizziness, and headache, with an incidence rate of 7-30%, and monitoring for potential bradycardia with donepezil in patients with cardiovascular history is recommended 4, 3, 2

Non-Pharmacological Interventions

• Group or individual physical exercise is recommended for people living with dementia to improve their physical and cognitive function, with a moderate level of evidence supporting this intervention 2
• Group cognitive stimulation therapy is recommended for mild to moderate dementia to improve cognitive function and quality of life, with a high level of evidence supporting this approach 2
• Reducing excess stimulation and clutter, and ensuring adequate lighting, especially at night, can contribute to a safer environment for patients with dementia, with a moderate level of evidence supporting these modifications 1, 2

Caregiver Support and End-of-Life Care

• Caregiver support through psychosocial and psychoeducational interventions is essential to reduce caregiver burden and improve patient outcomes, with a high level of evidence supporting this approach 1, 5
• As Alzheimer's progresses, shift focus to comfort care and quality of life, addressing nutrition, hydration, and infection management, discussing appropriateness of life-sustaining measures, intensifying symptom management for pain and distress, and initiating advance care planning while patient still has decision-making capacity, with a high level of evidence supporting this approach 1, 2
• Intensifying symptom management for pain, dyspnea, and other distressing symptoms is essential in end-of-life care, with a high level of evidence supporting this approach 6, 7
• Advance care planning should be initiated while the patient still has decision-making capacity, including documenting goals of care, treatment preferences, and end-of-life wishes, and identifying a substitute decision-maker/healthcare proxy, with a high level of evidence supporting this approach 7, 1

Discontinuation of Medication

• Consider discontinuing ChEIs or memantine if there is clinically meaningful worsening of dementia, no clinically meaningful benefit, development of severe or end-stage dementia, intolerable side effects, or poor medication adherence, with a moderate level of evidence supporting this approach 4, 2
• Do not discontinue ChEIs in patients with clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms have stabilized, with a high level of evidence supporting this approach 2
• When discontinuing medication, reduce dose by 50% every 4 weeks until reaching initial starting dose, and then discontinue completely, with a moderate level of evidence supporting this approach 2